董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| George Ng | 男 | Director | 52 | 22.95万美元 | 8.00 | 2026-08-18 |
| James Bianco | 男 | Chief Executive Officer and Director | 70 | 398.71万美元 | 308.55 | 2026-08-18 |
| James Manuso | 男 | Chairman of the Board and Director | 77 | 29.09万美元 | 4.70 | 2026-08-18 |
| Alan List | 男 | Director | 71 | 23.55万美元 | 4.42 | 2026-08-18 |
| Craig Tendler | 男 | Director | 67 | 26.69万美元 | 5.06 | 2026-08-18 |
| Robert E. Hoffman | 男 | Director | 60 | 21.20万美元 | 2.43 | 2026-08-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James Bianco | 男 | Chief Executive Officer and Director | 70 | 398.71万美元 | 308.55 | 2026-08-18 |
| Dan Dearborn | 男 | Chief Financial Officer | 59 | 183.20万美元 | 52.45 | 2026-08-18 |
董事简历
中英对照 | 中文 | 英文- George Ng
-
George Ng，自2020年2月起担任Legacy TuHURA董事，并在Kintara Merger合并完成后被任命为TuHURA董事会董事。Ng先生自2019年10月起担任Calidi Biotherapeutics， Inc. （NYSE American： CLDI）的董事，自2022年2月1日起担任其总裁兼首席运营官，以及自2023年8月8日起担任Processa Pharmaceuticals， Inc. （Nasdaq： PCSA）的董事兼首席执行官。此外，他目前是PENG Life Science Ventures的合伙人（2013年9月以来），IACTA Pharmaceuticals, Inc.的董事、联合创始人和首席商务官（2020年1月以来）。他的经验还包括在多家上市和私人全球生物技术和制药公司担任各种高管职位。Ng先生此前于2019年5月至2020年4月担任Inflammatory Response Research， Inc.董事，2019年7月至2020年1月担任Invent Medical Corp董事，2016年6月至2019年担任ImmuneOncia Therapeutics Inc.董事，并于2017年4月至2019年4月担任Virttu Biologics Limited董事。2015年3月至2019年4月，Ng先生还担任Sorrento Therapeutics， Inc.（纳斯达克股票代码：SRNE）的执行副总裁兼首席行政官；2012年9月至2019年4月，担任Scilex Pharmaceuticals Inc.的联合创始人兼业务总裁；2012年12月至2015年3月，担任BioDelivery Sciences International Inc.（纳斯达克股票代码：BDSI）的高级副总裁兼总法律顾问。他持有Notre Dame大学School of Law的法学博士学位，以及California大学， Davis的生物化学和经济学双学位。
George Ng has served as Processa Pharmaceutcals, Inc.'s Chief Executive Officer and as a director since August 8, 2023. He has served as a member of the board of directors of Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi") from October 2019 to September 2024, and was Calidi's President and Chief Operating Officer from February 1, 2022 until June 23, 2023. He has been a partner at PENG Life Science Ventures since September 2013; a member of the board of directors and co founder at IACTA Pharmaceuticals, Inc. since January 2020; and member of the board of directors of TuHURA Biosciences, Inc. (formerly, Morphogenesis, Inc.) since February 2020. His experience further includes serving in various executive level or board of director positions for multiple publicly traded and private global biotechnology and pharmaceutical firms. Mr. Ng previously served as a member of the board of directors of Inflammatory Response Research, Inc. from May 2019 to April 2020; Invent Medical Corp from July 2019 to January 2020; ImmuneOncia Therapeutics Inc. from June 2016 to 2019; and Virttu Biologics Limited from April 2017 to April 2019. He was also the Executive Vice President and Chief Administrative Officer of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) from March 2015 to April 2019; the Co Founder and President, Business of Scilex Pharmaceuticals Inc. from September 2012 to April 2019; and the Senior Vice President and General Counsel of BioDelivery Sciences International Inc. (Nasdaq: BDSI) from December 2012 to March 2015. Mr. Ng holds a JD degree from the University of Notre Dame School of Law, as well as a B.A.S. (B.A. and B.S.) dual degree in Biochemistry and Economics from the University of California, Davis. - George Ng，自2020年2月起担任Legacy TuHURA董事，并在Kintara Merger合并完成后被任命为TuHURA董事会董事。Ng先生自2019年10月起担任Calidi Biotherapeutics， Inc. （NYSE American： CLDI）的董事，自2022年2月1日起担任其总裁兼首席运营官，以及自2023年8月8日起担任Processa Pharmaceuticals， Inc. （Nasdaq： PCSA）的董事兼首席执行官。此外，他目前是PENG Life Science Ventures的合伙人（2013年9月以来），IACTA Pharmaceuticals, Inc.的董事、联合创始人和首席商务官（2020年1月以来）。他的经验还包括在多家上市和私人全球生物技术和制药公司担任各种高管职位。Ng先生此前于2019年5月至2020年4月担任Inflammatory Response Research， Inc.董事，2019年7月至2020年1月担任Invent Medical Corp董事，2016年6月至2019年担任ImmuneOncia Therapeutics Inc.董事，并于2017年4月至2019年4月担任Virttu Biologics Limited董事。2015年3月至2019年4月，Ng先生还担任Sorrento Therapeutics， Inc.（纳斯达克股票代码：SRNE）的执行副总裁兼首席行政官；2012年9月至2019年4月，担任Scilex Pharmaceuticals Inc.的联合创始人兼业务总裁；2012年12月至2015年3月，担任BioDelivery Sciences International Inc.（纳斯达克股票代码：BDSI）的高级副总裁兼总法律顾问。他持有Notre Dame大学School of Law的法学博士学位，以及California大学， Davis的生物化学和经济学双学位。
- George Ng has served as Processa Pharmaceutcals, Inc.'s Chief Executive Officer and as a director since August 8, 2023. He has served as a member of the board of directors of Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi") from October 2019 to September 2024, and was Calidi's President and Chief Operating Officer from February 1, 2022 until June 23, 2023. He has been a partner at PENG Life Science Ventures since September 2013; a member of the board of directors and co founder at IACTA Pharmaceuticals, Inc. since January 2020; and member of the board of directors of TuHURA Biosciences, Inc. (formerly, Morphogenesis, Inc.) since February 2020. His experience further includes serving in various executive level or board of director positions for multiple publicly traded and private global biotechnology and pharmaceutical firms. Mr. Ng previously served as a member of the board of directors of Inflammatory Response Research, Inc. from May 2019 to April 2020; Invent Medical Corp from July 2019 to January 2020; ImmuneOncia Therapeutics Inc. from June 2016 to 2019; and Virttu Biologics Limited from April 2017 to April 2019. He was also the Executive Vice President and Chief Administrative Officer of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) from March 2015 to April 2019; the Co Founder and President, Business of Scilex Pharmaceuticals Inc. from September 2012 to April 2019; and the Senior Vice President and General Counsel of BioDelivery Sciences International Inc. (Nasdaq: BDSI) from December 2012 to March 2015. Mr. Ng holds a JD degree from the University of Notre Dame School of Law, as well as a B.A.S. (B.A. and B.S.) dual degree in Biochemistry and Economics from the University of California, Davis.
- James Bianco
-
James A. Bianco是美国公民，曾任联合国副秘书长。
James Bianco is a 33 year veteran of the biopharmaceutical industry. Dr. Bianco is the principal founder of CTI Biopharma, where he served as its CEO from 1992 to October 2016. Dr. Bianco's experience spans all aspects of drug development from phase I IV clinical trials, regulatory approval, and pricing reimbursement to sales and marketing. He has extensive experience in financing, negotiating and execution of pharmaceutical development and commercial license agreements. During his tenure at CTI Biopharma, Dr. Bianco was responsible for strategic portfolio development and identifying, acquiring, licensing, purchasing, or acquiring through international merger and acquisition, five drug candidates, four of which have since been approved by the FDA and with three receiving accelerated or conditional regulatory approval in the U.S. and/or E.U. In 2013, Dr. Bianco led CTI Biopharma in the identification and negotiation of the asset purchase for VONJO[] (pacritinib), a novel JAK2 selective tyrosine kinase inhibitor. He also led CTI Biopharma in the negotiation of the development and commercial license agreement with Baxalta. As CEO of CTI Biopharma, Dr. Bianco was also responsible for the PERSIST 2 Phase 3 trial design and conduct, the successful results of which served as the basis for the 2022 FDA accelerated approval of Vonjo[] (pacritinib) and the subsequent acquisition of CTI Biopharma by SOBI for $1.75 billion. Dr. Bianco joined Legacy TuHURA in 2021 as Tuhura Biosciences, Inc.'s Chief Executive Officer and as a director. He directed the completion of Tuhura Biosciences, Inc.'s reverse merger transaction with Kintara Therapeutics, Inc. in October 2024 (the "Kintara Merger"), and for TuHURA Biosciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Legacy TuHURA"), prior to the Kintara Merger since July 1, 2021. Dr. Bianco was also the founder, Chief Executive Officer and Chairman of TuHURA Biopharma, Inc., a biotechnology company, from its inception in November 2018 through its dissolution in January 2023, following the transfer of its assets to us. - James A. Bianco是美国公民，曾任联合国副秘书长。
- James Bianco is a 33 year veteran of the biopharmaceutical industry. Dr. Bianco is the principal founder of CTI Biopharma, where he served as its CEO from 1992 to October 2016. Dr. Bianco's experience spans all aspects of drug development from phase I IV clinical trials, regulatory approval, and pricing reimbursement to sales and marketing. He has extensive experience in financing, negotiating and execution of pharmaceutical development and commercial license agreements. During his tenure at CTI Biopharma, Dr. Bianco was responsible for strategic portfolio development and identifying, acquiring, licensing, purchasing, or acquiring through international merger and acquisition, five drug candidates, four of which have since been approved by the FDA and with three receiving accelerated or conditional regulatory approval in the U.S. and/or E.U. In 2013, Dr. Bianco led CTI Biopharma in the identification and negotiation of the asset purchase for VONJO[] (pacritinib), a novel JAK2 selective tyrosine kinase inhibitor. He also led CTI Biopharma in the negotiation of the development and commercial license agreement with Baxalta. As CEO of CTI Biopharma, Dr. Bianco was also responsible for the PERSIST 2 Phase 3 trial design and conduct, the successful results of which served as the basis for the 2022 FDA accelerated approval of Vonjo[] (pacritinib) and the subsequent acquisition of CTI Biopharma by SOBI for $1.75 billion. Dr. Bianco joined Legacy TuHURA in 2021 as Tuhura Biosciences, Inc.'s Chief Executive Officer and as a director. He directed the completion of Tuhura Biosciences, Inc.'s reverse merger transaction with Kintara Therapeutics, Inc. in October 2024 (the "Kintara Merger"), and for TuHURA Biosciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Legacy TuHURA"), prior to the Kintara Merger since July 1, 2021. Dr. Bianco was also the founder, Chief Executive Officer and Chairman of TuHURA Biopharma, Inc., a biotechnology company, from its inception in November 2018 through its dissolution in January 2023, following the transfer of its assets to us.
- James Manuso
-
James Manuso，自2022年11月起担任Legacy TuHURA的董事，并在Kintara合并完成后被任命为TuHURA的董事兼董事会主席。自2014年以来，Manuso博士还担任投资实体和财务咨询公司Talfinium Investments，Inc.的董事长兼首席执行官。自2018年以来，马努索博士一直担任由他创立的家族办公室Laurelside LLC的管理成员。Manuso博士自2020年11月起担任Ocuphire Pharma, Inc.的董事会成员，该公司是一家上市公司（纳斯达克股票代码：OCUP），在治疗多种视觉障碍的先进临床试验中开发Nyxol。从2015年到2018年，Manuso博士担任RespireRx Pharmaceuticals Inc.（OTC QB：RSPI）的总裁、首席执行官和副主席，该公司是一家3期就绪、临床阶段的呼吸和神经系统制药公司。2011年7月至2013年10月，Manuso博士担任Astex Pharmaceuticals, Inc.（纳斯达克：ASTX）的董事长兼首席执行官，并牵头将超基因，Inc.出售给大冢制药（Otsuka Pharmaceutical Co.，Ltd.，Ltd.）（“大冢制药”）。2013年，他是大冢制药执行管理层的高级并购顾问。Manuso博士曾担任多家公司董事会的董事会主席和审计、治理和提名、定价和薪酬委员会主席，包括生物技术行业组织、Novelos Therapeutics，Inc.、Merrion Pharmaceuticals Ltd.（MERR：IEX；爱尔兰都柏林）、Inflazyme Pharmaceuticals，Inc.（IZP-TSE；加拿大温哥华）、他共同创立的Symbiontics，Inc.（以ZYStor，Inc.的名义出售给BioMarin Pharmaceutical Inc.）、Montigen Pharmaceuticals，Inc.、Quark Pharmaceuticals，Inc.、Galenica Pharmaceuticals，Inc.、Supratek Pharma，Inc.、EuroGen，Ltd.（英国伦敦），以及大旧金山Manuso拥有纽约大学经济学和化学荣誉学士学位、新学院大学实验心理学和遗传学博士学位，以及哥伦比亚商学院执行MBA学位。Manuso博士是许多章节、文章和书籍的作者，主题包括医疗保健成本控制和生物技术公司管理。
James Manuso served as a director of Legacy TuHURA since its founding and has served a director and Tuhura Biosciences, Inc.'s Chairman since the completion of the Kintara Merger in October 2024. Dr. Manuso has served as Chairman and Chief Executive Officer of Talfinium Investments, Inc. and as managing member of the Laurelside portfolio of LLCs, investment entities which he founded in 2014. Since 2020 Dr. Manuso has served on the board of Opus Genetics Inc. (IRD:Nasdaq), a commercial and clinical stage, ophthalmic biopharmaceutical company developing important new therapies for the treatment of inherited retinal diseases and other retinal and refractive disorders. From 2015 until 2018, Dr. Manuso served as President, Chief Executive Officer and Vice Chairman of RespireRx Pharmaceuticals Inc. (OTC QB:RSPI), a clinical stage biotechnology company. From January 2003 until October 2013, he served as Chairman, President and Chief Executive Officer of Astex Pharmaceuticals, Inc. (Nasdaq:ASTX; formerly SuperGen Nasdaq:SUPG), a commercial stage, oncology focused company which was sold to Otsuka Pharmaceutical Co., Ltd. in 2013. Dr. Manuso holds a B.A. with honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychology and Gnetics from the New School University, and an Executive M.B.A. from Columbia Business School. Dr. Manuso is an author of numerous chapters, articles, patents and books on topics including health care cost containment and biotechnology company foundation and management. - James Manuso，自2022年11月起担任Legacy TuHURA的董事，并在Kintara合并完成后被任命为TuHURA的董事兼董事会主席。自2014年以来，Manuso博士还担任投资实体和财务咨询公司Talfinium Investments，Inc.的董事长兼首席执行官。自2018年以来，马努索博士一直担任由他创立的家族办公室Laurelside LLC的管理成员。Manuso博士自2020年11月起担任Ocuphire Pharma, Inc.的董事会成员，该公司是一家上市公司（纳斯达克股票代码：OCUP），在治疗多种视觉障碍的先进临床试验中开发Nyxol。从2015年到2018年，Manuso博士担任RespireRx Pharmaceuticals Inc.（OTC QB：RSPI）的总裁、首席执行官和副主席，该公司是一家3期就绪、临床阶段的呼吸和神经系统制药公司。2011年7月至2013年10月，Manuso博士担任Astex Pharmaceuticals, Inc.（纳斯达克：ASTX）的董事长兼首席执行官，并牵头将超基因，Inc.出售给大冢制药（Otsuka Pharmaceutical Co.，Ltd.，Ltd.）（“大冢制药”）。2013年，他是大冢制药执行管理层的高级并购顾问。Manuso博士曾担任多家公司董事会的董事会主席和审计、治理和提名、定价和薪酬委员会主席，包括生物技术行业组织、Novelos Therapeutics，Inc.、Merrion Pharmaceuticals Ltd.（MERR：IEX；爱尔兰都柏林）、Inflazyme Pharmaceuticals，Inc.（IZP-TSE；加拿大温哥华）、他共同创立的Symbiontics，Inc.（以ZYStor，Inc.的名义出售给BioMarin Pharmaceutical Inc.）、Montigen Pharmaceuticals，Inc.、Quark Pharmaceuticals，Inc.、Galenica Pharmaceuticals，Inc.、Supratek Pharma，Inc.、EuroGen，Ltd.（英国伦敦），以及大旧金山Manuso拥有纽约大学经济学和化学荣誉学士学位、新学院大学实验心理学和遗传学博士学位，以及哥伦比亚商学院执行MBA学位。Manuso博士是许多章节、文章和书籍的作者，主题包括医疗保健成本控制和生物技术公司管理。
- James Manuso served as a director of Legacy TuHURA since its founding and has served a director and Tuhura Biosciences, Inc.'s Chairman since the completion of the Kintara Merger in October 2024. Dr. Manuso has served as Chairman and Chief Executive Officer of Talfinium Investments, Inc. and as managing member of the Laurelside portfolio of LLCs, investment entities which he founded in 2014. Since 2020 Dr. Manuso has served on the board of Opus Genetics Inc. (IRD:Nasdaq), a commercial and clinical stage, ophthalmic biopharmaceutical company developing important new therapies for the treatment of inherited retinal diseases and other retinal and refractive disorders. From 2015 until 2018, Dr. Manuso served as President, Chief Executive Officer and Vice Chairman of RespireRx Pharmaceuticals Inc. (OTC QB:RSPI), a clinical stage biotechnology company. From January 2003 until October 2013, he served as Chairman, President and Chief Executive Officer of Astex Pharmaceuticals, Inc. (Nasdaq:ASTX; formerly SuperGen Nasdaq:SUPG), a commercial stage, oncology focused company which was sold to Otsuka Pharmaceutical Co., Ltd. in 2013. Dr. Manuso holds a B.A. with honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychology and Gnetics from the New School University, and an Executive M.B.A. from Columbia Business School. Dr. Manuso is an author of numerous chapters, articles, patents and books on topics including health care cost containment and biotechnology company foundation and management.
- Alan List
-
Alan List，自2022年11月起担任Legacy TuHURA的董事，并在Kintara合并完成后被任命为TuHURA董事会董事。List博士还自2021年4月起担任临床阶段基因编辑公司Precision生物科学，Inc.（纳斯达克：DTIL）（“Precision生物科学”）的首席医疗官，在此之前，自2020年4月起担任Precision生物科学及其董事会的战略临床顾问，就其临床阶段和临床前同种异体CAR T项目提供建议。在加入Precision生物科学之前，List博士曾在莫菲特癌症中心担任过各种职务，包括2012年至2019年12月担任总裁兼首席执行官，2008年至2012年担任执行副总裁、主任医师，以及2003年至2008年担任恶性血液学处处长。在加入莫菲特癌症中心之前，李斯特博士在亚利桑那大学担任学术和临床任命。李斯特博士因其在开发骨髓增生异常综合征（“MDS”）和急性髓细胞白血病的有效治疗策略方面的诸多贡献而获得国际认可。他的开创性工作导致了Revlimid（来那度胺）的开发，这是一种治疗MDS和多发性骨髓瘤患者的转化疗法。李斯特是众多同行评议文章和书籍的作者。他此前曾担任血液肿瘤学会会长以及MDS基金会董事会成员。李斯特博士也是美国临床肿瘤学会、美国血液学会和美国癌症研究协会的活跃成员。他是美国国家发明家学会的特许研究员，也是佛罗里达州发明家Hall of Fame的入选者。李斯特博士在巴克内尔大学获得学士和硕士学位，并在宾夕法尼亚大学获得医学博士学位。他在内科、血液科、内科肿瘤科获得董事会认证。
Alan List served as a director of Legacy TuHURA prior to the Kintara Merger since November 2022 and has served as a director of Tuhura Biosciences, Inc.'s company since the completion of the Kintara Merger. Dr. List currently serves as Chief Scientific Officer of Stelexis BioSciences, Inc., and has also served as Chief Medical Officer of Precision BioSciences, Inc. (Nasdaq: DTIL) ("Precision BioSciences"), a clinical stage gene editing company, from April 2021 through September 2024. Prior to that, he had been a strategic clinical advisor to Precision BioSciences and its board since April 2020, providing advice regarding its clinical stage and pre clinical allogeneic CAR T programs. Prior to joining Precision BioSciences, Dr. List served in various roles at the Moffitt Cancer Center, including as President and Chief Executive Officer from 2012 to December 2019, Executive Vice President, Physician in Chief from 2008 to 2012 and Chief of the Malignant Hematology Department from 2003 to 2008. Prior to joining the Moffitt Cancer Center, Dr. List held academic and clinical appointments at the University of Arizona. He is a Charter Fellow in the National Academy of Inventors and an inductee in the Florida Inventors Hall of Fame. Dr. List received B.S. and M.S. degrees from Bucknell University and earned his M.D. from the University of Pennsylvania. He completed his fellowship in Hematology and Medical Oncology at Vanderbilt University Medical Center, and is board certified in internal medicine, hematology, and medical oncology. - Alan List，自2022年11月起担任Legacy TuHURA的董事，并在Kintara合并完成后被任命为TuHURA董事会董事。List博士还自2021年4月起担任临床阶段基因编辑公司Precision生物科学，Inc.（纳斯达克：DTIL）（“Precision生物科学”）的首席医疗官，在此之前，自2020年4月起担任Precision生物科学及其董事会的战略临床顾问，就其临床阶段和临床前同种异体CAR T项目提供建议。在加入Precision生物科学之前，List博士曾在莫菲特癌症中心担任过各种职务，包括2012年至2019年12月担任总裁兼首席执行官，2008年至2012年担任执行副总裁、主任医师，以及2003年至2008年担任恶性血液学处处长。在加入莫菲特癌症中心之前，李斯特博士在亚利桑那大学担任学术和临床任命。李斯特博士因其在开发骨髓增生异常综合征（“MDS”）和急性髓细胞白血病的有效治疗策略方面的诸多贡献而获得国际认可。他的开创性工作导致了Revlimid（来那度胺）的开发，这是一种治疗MDS和多发性骨髓瘤患者的转化疗法。李斯特是众多同行评议文章和书籍的作者。他此前曾担任血液肿瘤学会会长以及MDS基金会董事会成员。李斯特博士也是美国临床肿瘤学会、美国血液学会和美国癌症研究协会的活跃成员。他是美国国家发明家学会的特许研究员，也是佛罗里达州发明家Hall of Fame的入选者。李斯特博士在巴克内尔大学获得学士和硕士学位，并在宾夕法尼亚大学获得医学博士学位。他在内科、血液科、内科肿瘤科获得董事会认证。
- Alan List served as a director of Legacy TuHURA prior to the Kintara Merger since November 2022 and has served as a director of Tuhura Biosciences, Inc.'s company since the completion of the Kintara Merger. Dr. List currently serves as Chief Scientific Officer of Stelexis BioSciences, Inc., and has also served as Chief Medical Officer of Precision BioSciences, Inc. (Nasdaq: DTIL) ("Precision BioSciences"), a clinical stage gene editing company, from April 2021 through September 2024. Prior to that, he had been a strategic clinical advisor to Precision BioSciences and its board since April 2020, providing advice regarding its clinical stage and pre clinical allogeneic CAR T programs. Prior to joining Precision BioSciences, Dr. List served in various roles at the Moffitt Cancer Center, including as President and Chief Executive Officer from 2012 to December 2019, Executive Vice President, Physician in Chief from 2008 to 2012 and Chief of the Malignant Hematology Department from 2003 to 2008. Prior to joining the Moffitt Cancer Center, Dr. List held academic and clinical appointments at the University of Arizona. He is a Charter Fellow in the National Academy of Inventors and an inductee in the Florida Inventors Hall of Fame. Dr. List received B.S. and M.S. degrees from Bucknell University and earned his M.D. from the University of Pennsylvania. He completed his fellowship in Hematology and Medical Oncology at Vanderbilt University Medical Center, and is board certified in internal medicine, hematology, and medical oncology.
- Craig Tendler
-
Craig Tendler，于2025年3月10日被任命为TuHURA董事会成员。Tendler博士是一位经验丰富的制药和生物技术行业专业人士。从2010年1月到2024年12月，Tendler博士担任强生创新药研发公司肿瘤临床开发、诊断和全球医疗事务副总裁，负责制定和监督稳健的发展计划，包括生物标志物和诊断的优化整合，以及肿瘤学产品组合中所有产品的综合数据生成活动。在强生任职期间，Tendler博士和他的团队与FDA和欧洲药品管理局合作，以确保前列腺癌、血液系统恶性肿瘤以及午餐和膀胱癌的转化治疗在全球范围内获得批准。他在加速早期开发用于治疗严重肿瘤疾病的有前景的研究药物方面，在实现13项FDA突破性指定方面发挥了重要作用。在加入强生创新药之前，Tendler博士曾在Schering-Plough研究所担任肿瘤学临床研究副总裁和肿瘤学许可委员会主席。除了制药行业的经验，Tendler博士还曾担任癌症研究之友企业委员会的联合主席、彭博新经济国际癌症联盟成员，以及西奈山医学院招生委员会成员。Tendler博士是西奈山医学院的儿科/血液肿瘤学助理教授，也是马里兰州贝塞斯达国家癌症研究所的NIH医师科学家资助获得者和研究员。Tendler博士获得了康奈尔大学的本科学位，并以优异的成绩毕业于纽约市西奈山医学院，并入选了Alpha Omega Alpha医学会。
Craig Tendler has also provided consulting services to the Company through an affiliated entity. Dr. Tendler is an experienced pharmaceutical and biotech industry professional. From January 2010 through December 2024, Dr. Tendler served as the Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs of Johnson & Johnson Innovative Medicine Research & Development where he was responsible for creating and overseeing robust development plans, including optimal integration of biomarkers and diagnostics, and comprehensive data generation activities for all products in the oncology portfolio. During his tenure at Johnson & Johnson, Dr. Tendler and his team worked in collaboration with the FDA and the European Medicines Agency to secure worldwide approvals of transformational treatments in prostate cancer, hematologic malignancies, as well as for lung and bladder cancer. He played an instrumental role in achieving 13 FDA breakthrough designations for accelerating the early development of promising investigational medicines intended for the treatment of serious oncology conditions. Dr. Tendler was an Assistant Professor of Pediatrics/Hematology Oncology at the Mount Sinai School of Medicine and a NIH physician scientist grant recipient and research fellow at the National Cancer Institute in Bethesda, Maryland. Dr. Tendler earned his undergraduate degree from Cornell University and graduated from the Mount Sinai School of Medicine, New York City, with high honors and induction into the Alpha Omega Alpha Medical Society. - Craig Tendler，于2025年3月10日被任命为TuHURA董事会成员。Tendler博士是一位经验丰富的制药和生物技术行业专业人士。从2010年1月到2024年12月，Tendler博士担任强生创新药研发公司肿瘤临床开发、诊断和全球医疗事务副总裁，负责制定和监督稳健的发展计划，包括生物标志物和诊断的优化整合，以及肿瘤学产品组合中所有产品的综合数据生成活动。在强生任职期间，Tendler博士和他的团队与FDA和欧洲药品管理局合作，以确保前列腺癌、血液系统恶性肿瘤以及午餐和膀胱癌的转化治疗在全球范围内获得批准。他在加速早期开发用于治疗严重肿瘤疾病的有前景的研究药物方面，在实现13项FDA突破性指定方面发挥了重要作用。在加入强生创新药之前，Tendler博士曾在Schering-Plough研究所担任肿瘤学临床研究副总裁和肿瘤学许可委员会主席。除了制药行业的经验，Tendler博士还曾担任癌症研究之友企业委员会的联合主席、彭博新经济国际癌症联盟成员，以及西奈山医学院招生委员会成员。Tendler博士是西奈山医学院的儿科/血液肿瘤学助理教授，也是马里兰州贝塞斯达国家癌症研究所的NIH医师科学家资助获得者和研究员。Tendler博士获得了康奈尔大学的本科学位，并以优异的成绩毕业于纽约市西奈山医学院，并入选了Alpha Omega Alpha医学会。
- Craig Tendler has also provided consulting services to the Company through an affiliated entity. Dr. Tendler is an experienced pharmaceutical and biotech industry professional. From January 2010 through December 2024, Dr. Tendler served as the Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs of Johnson & Johnson Innovative Medicine Research & Development where he was responsible for creating and overseeing robust development plans, including optimal integration of biomarkers and diagnostics, and comprehensive data generation activities for all products in the oncology portfolio. During his tenure at Johnson & Johnson, Dr. Tendler and his team worked in collaboration with the FDA and the European Medicines Agency to secure worldwide approvals of transformational treatments in prostate cancer, hematologic malignancies, as well as for lung and bladder cancer. He played an instrumental role in achieving 13 FDA breakthrough designations for accelerating the early development of promising investigational medicines intended for the treatment of serious oncology conditions. Dr. Tendler was an Assistant Professor of Pediatrics/Hematology Oncology at the Mount Sinai School of Medicine and a NIH physician scientist grant recipient and research fellow at the National Cancer Institute in Bethesda, Maryland. Dr. Tendler earned his undergraduate degree from Cornell University and graduated from the Mount Sinai School of Medicine, New York City, with high honors and induction into the Alpha Omega Alpha Medical Society.
- Robert E. Hoffman
-
Robert E. Hoffman，自2018年4月起担任Kintara Therapeutics，Inc.董事，自2018年6月起担任Kintara Therapeutics, Inc.董事长，自2021年11月起担任Kintara Therapeutics, Inc.首席执行官兼总裁，自2023年6月起担任Kintara Therapeutics，Inc.临时首席财务官。自2018年10月起，他担任亚狮康药业，Inc.的董事会成员，该公司是一家上市的、专注于临床阶段免疫学的生物制药公司，自2021年4月起担任FibroGenesis，一家临床阶段再生医学公司的董事会成员。他还曾于2020年11月至2024年4月担任上市临床阶段生物技术公司Antibe Therapeutics Inc.（“Antibe”）的董事会成员、审计委员会成员、人力资源和薪酬委员会成员，并于2022年5月至2024年4月担任Antibe董事会主席。Hoffman先生于2017年4月至2020年10月期间担任上市制药公司Heron Therapeutics, Inc.的高级副总裁兼首席财务官。2015年7月至2016年9月，Hoffman先生在上市生物技术公司AnaptysBio，Inc.担任首席财务官。2012年6月至2015年7月，Hoffman先生在2022年3月被辉瑞 Inc.收购之前，曾担任生物制药公司Arena Pharmaceuticals, Inc.（“Arena”）的财务高级副总裁兼首席财务官。2011年8月至2012年6月，此前的2005年12月至2011年3月，他担任Arena的财务副总裁兼首席财务官，并于1997年至2005年12月担任多个职责不断增加的职务。Hoffman先生曾于2021年9月至2022年5月担任生物制药公司Saniona AB的董事会成员，并于2015年3月至2021年8月担任癌症研究公司Kura Oncology, Inc.的董事会成员。他此前还曾担任分子诊断公司CombiMatrix Corporation、生物制药公司MabVax Therapeutics Holdings，Inc.和临床阶段生物技术公司Aravive, Inc.的董事会成员。Hoffman先生担任生物科学财务官员协会指导委员会成员。Hoffman先生曾担任Financial Executives International圣地亚哥分会的董事和总裁，并担任财务会计准则委员会（FASB）的顾问长达10年（2010年至2020年），就新出现的问题和新的财务指导向美国会计规则制定组织提供建议。Hoffman先生拥有圣博纳文大学的学士学位。
Robert E. Hoffman served as a director of Tuhura Biosciences, Inc.'s Company from April 2018 through the completion of the Kintara Merger, as Chairman of Kintara from June 2018 through the completion of the Kintara Merger, as Chief Executive Officer and President of Kintara from November 2021 through the completion of the Kintara Merger, and as interim Chief Financial Officer of Kintara from June 1, 2023, through the completion of the Kintara Merger. Mr. Hoffman has also continued to serve as a director since completion of the Kintara Merger. Mr. Hoffman is the Chief Financial Officer of CytoDyn Inc. (OTC: CYDY), a publicly held, clinical stage oncology company since May 2025. Mr. Hoffman formerly served as a member of the board of directors of Saniona AB, a biopharmaceutical company, from September 2021 to May 2022, and as a member of the board of directors of Kura Oncology, Inc., a cancer research company, from March 2015 to August 2021. He also previously served as a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company, MabVax Therapeutics Holdings, Inc., a biopharmaceutical company, and Aravive, Inc., a clinical stage biotechnology company. Mr. Hoffman serves as a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standards Board (FASB) for 10 years (2010 to 2020) advising the United States accounting rulemaking organization on emerging issues and new financial guidance. Mr. Hoffman holds a B.B.A. from St. Bonaventure University. - Robert E. Hoffman，自2018年4月起担任Kintara Therapeutics，Inc.董事，自2018年6月起担任Kintara Therapeutics, Inc.董事长，自2021年11月起担任Kintara Therapeutics, Inc.首席执行官兼总裁，自2023年6月起担任Kintara Therapeutics，Inc.临时首席财务官。自2018年10月起，他担任亚狮康药业，Inc.的董事会成员，该公司是一家上市的、专注于临床阶段免疫学的生物制药公司，自2021年4月起担任FibroGenesis，一家临床阶段再生医学公司的董事会成员。他还曾于2020年11月至2024年4月担任上市临床阶段生物技术公司Antibe Therapeutics Inc.（“Antibe”）的董事会成员、审计委员会成员、人力资源和薪酬委员会成员，并于2022年5月至2024年4月担任Antibe董事会主席。Hoffman先生于2017年4月至2020年10月期间担任上市制药公司Heron Therapeutics, Inc.的高级副总裁兼首席财务官。2015年7月至2016年9月，Hoffman先生在上市生物技术公司AnaptysBio，Inc.担任首席财务官。2012年6月至2015年7月，Hoffman先生在2022年3月被辉瑞 Inc.收购之前，曾担任生物制药公司Arena Pharmaceuticals, Inc.（“Arena”）的财务高级副总裁兼首席财务官。2011年8月至2012年6月，此前的2005年12月至2011年3月，他担任Arena的财务副总裁兼首席财务官，并于1997年至2005年12月担任多个职责不断增加的职务。Hoffman先生曾于2021年9月至2022年5月担任生物制药公司Saniona AB的董事会成员，并于2015年3月至2021年8月担任癌症研究公司Kura Oncology, Inc.的董事会成员。他此前还曾担任分子诊断公司CombiMatrix Corporation、生物制药公司MabVax Therapeutics Holdings，Inc.和临床阶段生物技术公司Aravive, Inc.的董事会成员。Hoffman先生担任生物科学财务官员协会指导委员会成员。Hoffman先生曾担任Financial Executives International圣地亚哥分会的董事和总裁，并担任财务会计准则委员会（FASB）的顾问长达10年（2010年至2020年），就新出现的问题和新的财务指导向美国会计规则制定组织提供建议。Hoffman先生拥有圣博纳文大学的学士学位。
- Robert E. Hoffman served as a director of Tuhura Biosciences, Inc.'s Company from April 2018 through the completion of the Kintara Merger, as Chairman of Kintara from June 2018 through the completion of the Kintara Merger, as Chief Executive Officer and President of Kintara from November 2021 through the completion of the Kintara Merger, and as interim Chief Financial Officer of Kintara from June 1, 2023, through the completion of the Kintara Merger. Mr. Hoffman has also continued to serve as a director since completion of the Kintara Merger. Mr. Hoffman is the Chief Financial Officer of CytoDyn Inc. (OTC: CYDY), a publicly held, clinical stage oncology company since May 2025. Mr. Hoffman formerly served as a member of the board of directors of Saniona AB, a biopharmaceutical company, from September 2021 to May 2022, and as a member of the board of directors of Kura Oncology, Inc., a cancer research company, from March 2015 to August 2021. He also previously served as a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company, MabVax Therapeutics Holdings, Inc., a biopharmaceutical company, and Aravive, Inc., a clinical stage biotechnology company. Mr. Hoffman serves as a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standards Board (FASB) for 10 years (2010 to 2020) advising the United States accounting rulemaking organization on emerging issues and new financial guidance. Mr. Hoffman holds a B.B.A. from St. Bonaventure University.
高管简历
中英对照 | 中文 | 英文- James Bianco
James A. Bianco是美国公民，曾任联合国副秘书长。
James Bianco is a 33 year veteran of the biopharmaceutical industry. Dr. Bianco is the principal founder of CTI Biopharma, where he served as its CEO from 1992 to October 2016. Dr. Bianco's experience spans all aspects of drug development from phase I IV clinical trials, regulatory approval, and pricing reimbursement to sales and marketing. He has extensive experience in financing, negotiating and execution of pharmaceutical development and commercial license agreements. During his tenure at CTI Biopharma, Dr. Bianco was responsible for strategic portfolio development and identifying, acquiring, licensing, purchasing, or acquiring through international merger and acquisition, five drug candidates, four of which have since been approved by the FDA and with three receiving accelerated or conditional regulatory approval in the U.S. and/or E.U. In 2013, Dr. Bianco led CTI Biopharma in the identification and negotiation of the asset purchase for VONJO[] (pacritinib), a novel JAK2 selective tyrosine kinase inhibitor. He also led CTI Biopharma in the negotiation of the development and commercial license agreement with Baxalta. As CEO of CTI Biopharma, Dr. Bianco was also responsible for the PERSIST 2 Phase 3 trial design and conduct, the successful results of which served as the basis for the 2022 FDA accelerated approval of Vonjo[] (pacritinib) and the subsequent acquisition of CTI Biopharma by SOBI for $1.75 billion. Dr. Bianco joined Legacy TuHURA in 2021 as Tuhura Biosciences, Inc.'s Chief Executive Officer and as a director. He directed the completion of Tuhura Biosciences, Inc.'s reverse merger transaction with Kintara Therapeutics, Inc. in October 2024 (the "Kintara Merger"), and for TuHURA Biosciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Legacy TuHURA"), prior to he Kintara Merger since July 1, 2021. Dr. Bianco was also the founder, Chief Executive Officer and Chairman of TuHURA Biopharma, Inc., a biotechnology company, from its inception in November 2018 through its dissolution in January 2023, following the transfer of its assets to us.- James A. Bianco是美国公民，曾任联合国副秘书长。
- James Bianco is a 33 year veteran of the biopharmaceutical industry. Dr. Bianco is the principal founder of CTI Biopharma, where he served as its CEO from 1992 to October 2016. Dr. Bianco's experience spans all aspects of drug development from phase I IV clinical trials, regulatory approval, and pricing reimbursement to sales and marketing. He has extensive experience in financing, negotiating and execution of pharmaceutical development and commercial license agreements. During his tenure at CTI Biopharma, Dr. Bianco was responsible for strategic portfolio development and identifying, acquiring, licensing, purchasing, or acquiring through international merger and acquisition, five drug candidates, four of which have since been approved by the FDA and with three receiving accelerated or conditional regulatory approval in the U.S. and/or E.U. In 2013, Dr. Bianco led CTI Biopharma in the identification and negotiation of the asset purchase for VONJO[] (pacritinib), a novel JAK2 selective tyrosine kinase inhibitor. He also led CTI Biopharma in the negotiation of the development and commercial license agreement with Baxalta. As CEO of CTI Biopharma, Dr. Bianco was also responsible for the PERSIST 2 Phase 3 trial design and conduct, the successful results of which served as the basis for the 2022 FDA accelerated approval of Vonjo[] (pacritinib) and the subsequent acquisition of CTI Biopharma by SOBI for $1.75 billion. Dr. Bianco joined Legacy TuHURA in 2021 as Tuhura Biosciences, Inc.'s Chief Executive Officer and as a director. He directed the completion of Tuhura Biosciences, Inc.'s reverse merger transaction with Kintara Therapeutics, Inc. in October 2024 (the "Kintara Merger"), and for TuHURA Biosciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Legacy TuHURA"), prior to he Kintara Merger since July 1, 2021. Dr. Bianco was also the founder, Chief Executive Officer and Chairman of TuHURA Biopharma, Inc., a biotechnology company, from its inception in November 2018 through its dissolution in January 2023, following the transfer of its assets to us.
- Dan Dearborn
Dan Dearborn，2018年加入Legacy TuHURA，担任其首席财务官。Dearborn先生是一名注册会计师，拥有超过25年的金融经验，专门在医疗保健和生物技术公司工作。在加入TuHURA之前，2015年至2017年，Dearborn先生在MYMD制药公司担任首席财务官，该公司是一家新兴的生物技术公司。迪尔伯恩先生是马里兰州洛约拉大学的校友，在他职业生涯的早期就加入了安永会计师事务所。他在长期护理制药公司Pharmerica工作了十五年，并迅速晋升为董事一职。随后，他加入了BioDelivery科学国际，担任财务总监。在他任职于BioDelivery科学国际期间，这家公司签署了两份非常大的商业合作协议，并在纳斯达克上市。迪尔伯恩先生后来加入Welldyne，Inc.（“Welldyne”），担任其首席财务官。Welldyne是一家药房福利管理公司，在佛罗里达州和科罗拉多州也有几家相关的医疗保健业务，并雇用了员工。在他任职Welldyne期间，该公司被出售给了凯雷集团公司，后者是世界上最大的私募股权公司之一。
Dan Dearborn Dan Dearborn joined Legacy TuHURA in 2018 as its Chief Financial Officer and has served in this role for Tuhura Biosciences, Inc.'s company since the completion of the Kintara Merger. Mr. Dearborn is a CPA with over 25 years of finance experience exclusively with health care and biotechnology companies. Prior to joining Tuhura Biosciences, Inc.'s company, from 2015 to 2017, Mr. Dearborn was Chief Financial Officer at MYMD Pharmaceuticals, Inc., a biotechnology firm. Mr. Dearborn is an alumnus of Loyola University in Maryland and joined Ernst & Young early in his career. He was with Pharmerica, a long term care pharmaceutical company, for fifteen years and advanced subsequently to a Director role. He then moved to BioDelivery Sciences International as Controller. During his time at BioDelivery Sciences International, the company signed two very large commercial partnership agreements and became listed on Nasdaq. Mr. Dearborn later joined Welldyne, Inc. ("Welldyne") as its Chief Financial Officer. Welldyne is a pharmacy benefit manager that also had several related health care businesses and employed associates in Florida and Colorado. During his time with Welldyne, the company was sold to the private equity firm Carlyle Group, Inc.- Dan Dearborn，2018年加入Legacy TuHURA，担任其首席财务官。Dearborn先生是一名注册会计师，拥有超过25年的金融经验，专门在医疗保健和生物技术公司工作。在加入TuHURA之前，2015年至2017年，Dearborn先生在MYMD制药公司担任首席财务官，该公司是一家新兴的生物技术公司。迪尔伯恩先生是马里兰州洛约拉大学的校友，在他职业生涯的早期就加入了安永会计师事务所。他在长期护理制药公司Pharmerica工作了十五年，并迅速晋升为董事一职。随后，他加入了BioDelivery科学国际，担任财务总监。在他任职于BioDelivery科学国际期间，这家公司签署了两份非常大的商业合作协议，并在纳斯达克上市。迪尔伯恩先生后来加入Welldyne，Inc.（“Welldyne”），担任其首席财务官。Welldyne是一家药房福利管理公司，在佛罗里达州和科罗拉多州也有几家相关的医疗保健业务，并雇用了员工。在他任职Welldyne期间，该公司被出售给了凯雷集团公司，后者是世界上最大的私募股权公司之一。
- Dan Dearborn Dan Dearborn joined Legacy TuHURA in 2018 as its Chief Financial Officer and has served in this role for Tuhura Biosciences, Inc.'s company since the completion of the Kintara Merger. Mr. Dearborn is a CPA with over 25 years of finance experience exclusively with health care and biotechnology companies. Prior to joining Tuhura Biosciences, Inc.'s company, from 2015 to 2017, Mr. Dearborn was Chief Financial Officer at MYMD Pharmaceuticals, Inc., a biotechnology firm. Mr. Dearborn is an alumnus of Loyola University in Maryland and joined Ernst & Young early in his career. He was with Pharmerica, a long term care pharmaceutical company, for fifteen years and advanced subsequently to a Director role. He then moved to BioDelivery Sciences International as Controller. During his time at BioDelivery Sciences International, the company signed two very large commercial partnership agreements and became listed on Nasdaq. Mr. Dearborn later joined Welldyne, Inc. ("Welldyne") as its Chief Financial Officer. Welldyne is a pharmacy benefit manager that also had several related health care businesses and employed associates in Florida and Colorado. During his time with Welldyne, the company was sold to the private equity firm Carlyle Group, Inc.